IL1B and diabetic kidney disease: Under such conditions, anti-inflammatory and antifibrosis effects may facilitate the use of renal protective agents, such as adhesion molecule inhibitors, sodium-dependent glucose transporters 2 inhibitors, and IL-1β antagonists in combination with the conventional renin-angiotensin-aldosterone system (RAAS) inhibitors in patients with DKD (Lytvyn et al., 2020; Moisi et al., 2020; Moisi et al., 2021).